May 13 |
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
|
May 13 |
Voyager Therapeutics GAAP EPS of -$0.20 beats by $0.24, revenue of $19.5M beats by $10.02M
|
May 13 |
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
|
May 8 |
Voyager Therapeutics Presents Data for Second-Generation, TRACERâ„¢-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
|
May 6 |
Voyager Therapeutics' (NASDAQ:VYGR) three-year earnings growth trails the splendid shareholder returns
|
May 6 |
Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
|
May 3 |
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
|
May 2 |
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
|
Apr 22 |
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
|
Apr 16 |
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
|